Associations of Estrogen Receptor, Progesterone Receptor, Human Epidemic Growth Factor Receptor-2 and Ki-67 with Ultrasound Signs and Prognosis of Breast Cancer Patients

References

• Yamamoto-Ibusuki M, Yamamoto Y, Yamamoto S, et al. Comparison of prognostic values between combined immunohistochemical score of estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2, Ki-67 and the corresponding gene expression score in breast cancer. Mod Pathol. 2013;26(1):79–86. doi:10.1038/modpathol.2012.15122918168
   PubMed Web of Science ®Google Scholar
• Labrude P. The ephemeral historical museum of the Ecole Superieure de pharmacie de Nancy (1913–1937) Its collectionstoday. Rev Hist Pharm. 2014;62(381):47–60. doi:10.3406/pharm.2014.22696
   PubMedGoogle Scholar
• Tu DG, Yu Y, Lee CH, et al. Hinokitiol inhibits vasculogenic mimicry activity of breast cancer stem/progenitor cells through proteasome-mediated degradation of epidermal growth factor receptor. Oncol Lett. 2016;11(4):2934–2940. doi:10.3892/ol.2016.430027073579
   PubMed Web of Science ®Google Scholar
• Nie M, Qin Y, Zhu J, Li Y, Wang Z. Correlation between ultrasonic features and expression levels of C-erbB-2, VEGF and nm23 in breast cancer. Oncol Lett. 2018;16(2):1701–1707. doi:10.3892/ol.2018.877730008856
   PubMed Web of Science ®Google Scholar
• Xu J, Guo X, Jing M, Sun T. Prediction of tumor mutation burden in breast cancer based on the expression of ER, PR, HER-2, and Ki-67. Onco Targets Ther. 2018;11:2269–2275. doi:10.2147/OTT.S15983029719409
   PubMed Web of Science ®Google Scholar
• Tsai WC, Wei HK, Hung CF, et al. Better overall survival for breast cancer patients by adding breast ultrasound to follow-up examinations for early detection of locoregional recurrence-a Survival Impact Study. Ultrasound Med Biol. 2016;42(9):2058–2064. doi:10.1016/j.ultrasmedbio.2016.04.00327184247
   PubMed Web of Science ®Google Scholar
• Song B, Wang L, Zhang Y, et al. Combined detection of HER2, Ki67, and GSTP1 genes on the diagnosis and prognosis of breast cancer. Cancer Biother Radiopharm. 2019;34(2):85–90. doi:10.1089/cbr.2018.257030585764
   PubMed Web of Science ®Google Scholar
• Wang D, Zhu K, Tian J, et al. Clinicopathological and ultrasonic features of triple-negative breast cancers: a comparison with hormone receptor-positive/human epidermal growth factor receptor-2-negative breast cancers. Ultrasound Med Biol. 2018;44(5):1124–1132. doi:10.1016/j.ultrasmedbio.2018.01.01329482888
   PubMed Web of Science ®Google Scholar
• Yan J, Liu XL, Han LZ, et al. Relation between Ki-67, ER, PR, Her2/neu, p21, EGFR, and TOP II-alpha expression in invasive ductal breast cancer patients and correlations with prognosis. Asian Pac J Cancer Prev. 2015;16(2):823–829. doi:10.7314/APJCP.2015.16.2.82325684532
   PubMedGoogle Scholar
• Hongisto V, Aure MR, Makela R, Sahlberg KK. The HER2 amplicon includes several genes required for the growth and survival of HER2 positive breast cancer cells - a data description. Genom Data. 2014;2:249–253. doi:10.1016/j.gdata.2014.06.02526484103
   PubMedGoogle Scholar
• Shilova ON, Proshkina GM, Lebedenko EN, Deyev SM. Internalization and recycling of the HER2 receptor on human breast adenocarcinoma cells treated with targeted phototoxic protein DARPinminiSOG. Acta Naturae. 2015;7(3):126–132. doi:10.32607/20758251-2015-7-3-126-13226483969
   PubMed Web of Science ®Google Scholar
• Hao S, He ZX, Yu KD, Yang WT, Shao ZM. New insights into the prognostic value of Ki-67 labeling index in patients with triple-negative breast cancer. Oncotarget. 2016;7(17):24824–24831. doi:10.18632/oncotarget.853127050075
   PubMedGoogle Scholar
• Theriault RL, Carlson RW, Allred C, et al. Breast cancer, version 3.2013: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2013;11(7):753–760; quiz 761. doi:10.6004/jnccn.2013.0098
   PubMed Web of Science ®Google Scholar
• Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med. 2010;134(7):e48–e72. doi:10.5858/134.7.e4820586616
   PubMed Web of Science ®Google Scholar
• Abdollahi A, Etemadi M. Pathological characteristics of triple-negative breast cancer at Main Referral Teaching Hospital, April 2014 to April 2015, Tehran, Iran. Int J Hematol Oncol Stem Cell Res. 2016;10(4):200–205.27928473
   PubMedGoogle Scholar
• Ahn S, Lee J, Cho MS, Park S, Sung SH. Evaluation of Ki-67 index in core needle biopsies and matched breast cancer surgical specimens. Arch Pathol Lab Med. 2018;142(3):364–368. doi:10.5858/arpa.2017-0014-OA29144790
   PubMed Web of Science ®Google Scholar
• Wang XZ, Liu Q, Sun JJ, et al. Correlation between p53 and epidermal growth factor receptor expression in breast cancer classification. Genet Mol Res. 2015;14(2):4282–4290. doi:10.4238/2015.April.28.1025966200
   PubMed Web of Science ®Google Scholar
• Ejlertsen B, Aldridge J, Nielsen KV, et al. Prognostic and predictive role of ESR1 status for postmenopausal patients with endocrine-responsive early breast cancer in the Danish cohort of the BIG 1–98 trial. Ann Oncol. 2012;23(5):1138–1144. doi:10.1093/annonc/mdr43821986093
   PubMed Web of Science ®Google Scholar
• Ding L, Zhang Z, Xu Y, Zhang Y. Comparative study of Her-2, p53, Ki-67 expression and clinicopathological characteristics of breast cancer in a cohort of northern China female patients. Bioengineered. 2017;8(4):383–392. doi:10.1080/21655979.2016.123510128075663
   PubMed Web of Science ®Google Scholar
• Murthy P, Kidwell KM, Schott AF, et al. Clinical predictors of long-term survival in HER2-positive metastatic breast cancer. Breast Cancer Res Treat. 2016;155(3):589–595. doi:10.1007/s10549-016-3705-326875184
   PubMed Web of Science ®Google Scholar
• Liu L, Chen F, Zhao J, Yu H. Correlation between overall survival and other endpoints in metastatic breast cancer with second- or third-line chemotherapy: literature-based analysis of 24 randomized trials. Bull Cancer. 2016;103(4):336–344. doi:10.1016/j.bulcan.2016.01.00226874974
   PubMed Web of Science ®Google Scholar
• Shandiz FH, Shabahang H, Afzaljavan F, et al. Ki67 frequency in breast cancers without axillary lymph node involvement and its relation with disease-free survival. Asian Pac J Cancer Prev. 2016;17(3):1347–1350. doi:10.7314/APJCP.2016.17.3.134727039770
   PubMedGoogle Scholar
• Brisken C. Reply to is progesterone a neutral or protective factor for breast cancer? Nat Rev Cancer. 2014;14(2):146. doi:10.1038/nrc3518-c2
   PubMed Web of Science ®Google Scholar
• Ohara M, Matsuura K, Akimoto E, et al. Prognostic value of Ki67 and p53 in patients with estrogen receptor-positive and human epidermal growth factor receptor 2-negative breast cancer: validation of the cut-off value of the Ki67 labeling index as a predictive factor. Mol Clin Oncol. 2016;4(4):648–654. doi:10.3892/mco.2016.77627073684
   PubMedGoogle Scholar
• Kleer CG, Cao Q, Varambally S, et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci U S A. 2003;100(20):11606–11611. doi:10.1073/pnas.193374410014500907
   PubMed Web of Science ®Google Scholar